Has Eduardo Gonzalez received payments from drug or device companies?

Yes. Drug and device makers reported $18,284 in general payments to Eduardo Gonzalez across 706 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Eduardo Gonzalez did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Eduardo Gonzalez come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Eduardo Gonzalez

Family · El Paso, TXNPI 1043679756

Payments from drug & device makers

$18,284in general payments, 2019–2025

Across 706 payments — averaging $25.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

UCB, Inc.$4K
Novo Nordisk$3K
Lilly USA, LLC$2K
AbbVie$1K
Boehringer Ingelheim$761
Abbott$733
plus $7K from 38 others

What the payments were for

Consulting fees$3,84021%
Travel & lodging$820%
Food & beverage$14,33078%
Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
UCB, Inc.	3	$3,922
Novo Nordisk	124	$2,955
Lilly USA, LLC	104	$1,690
AbbVie	70	$1,384
Boehringer Ingelheim	27	$761
Abbott	22	$733
Amgen(2 entities)	36	$649
Bayer	45	$649
Johnson & Johnson(3 entities)	29	$601
GSK	31	$558
AstraZeneca	30	$492
Biohaven Pharmaceuticals, Inc.	16	$386
Medtronic	4	$321
Amarin Pharma, Inc.	15	$315
Pfizer	17	$290
Antares Pharma, Inc.	15	$280
Biohaven Pharmaceutical Holding Company Ltd.	13	$226
Fresenius Kabi USA, LLC	9	$218
Corcept Therapeutics	8	$204
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	13	$195
Radius Health, Inc.	11	$181
Takeda Pharmaceuticals U.S.A., Inc.	7	$127
Esperion Therapeutics, Inc.	7	$109
Sanofi-aventis U.S. LLC	1	$99
Nestle Healthcare Nutrition Inc.	6	$95
Novartis	1	$92
Aimmune Therapeutics, Inc.	4	$85
Exact Sciences	5	$82
Hologic Sales And Service, LLC	3	$70
Kowa Pharmaceuticals America, Inc.	5	$69
Genentech USA, Inc.	4	$64
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	3	$56
Axsome Therapeutics, Inc.	3	$50
Phathom Pharmaceuticals, Inc.	3	$50
Neurelis, Inc.	2	$35
Arbor Pharmaceuticals, Inc.	2	$34
Corium, LLC	1	$30
Chiesi USA, Inc.	1	$21
Teva Pharmaceuticals USA, Inc.	1	$21
Sandoz	1	$20
Dexcom, Inc.	1	$19
Merck	1	$17
Lundbeck LLC	1	$14
Cumberland Pharmaceuticals, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,284 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	63	$136,089
TrulicityDulaglutide	28	$52,862
Synjardy XrEmpagliflozin/Metformin Hcl	32	$41,981
FarxigaDapagliflozin Propanediol	31	$40,402
MounjaroTirzepatide	13	$33,970
JardianceEmpagliflozin	24	$26,062
Tresiba Flextouch U-200Insulin Degludec	24	$24,534
LinzessLinaclotide	19	$21,225
Soliqua 100-33Insulin Glargine/Lixisenatide	16	$17,248
Xigduo XrDapaglifloz Propaned/Metformin	15	$15,485
JanuviaSitagliptin Phosphate	12	$14,206
MyrbetriqMirabegron	16	$10,858
Clonidine	11	$4,018
Pioglitazone Hcl	137	$2,100
Gabapentin	70	$1,744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Novo NordiskOzempic	$2,955	$136,08963 claims
Lilly USA, LLCTrulicity, Mounjaro	$1,690	$86,83241 claims
Boehringer IngelheimSynjardy Xr, Jardiance	$761	$68,04356 claims
AstraZenecaFarxiga	$492	$40,40231 claims
AbbVieLinzess	$1,384	$21,22519 claims
Sanofi-aventis U.S. LLCSoliqua 100-33	$99	$17,24816 claims
MerckJanuvia	$17	$14,20612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in El Paso

Margarita FavelaEl Paso$73K
Lashonda CraneHouston$3.4M
David WeirDallas$959K
Luba YammineHouston$479K
Robin BeachHouston$428K
Nirupama JeromeAustin$418K
April LopezMcAllen$417K
Linda MercadoHouston$211K
Sarah AguilarHouston$199K
Sie ThomasDallas$197K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →